Petrovic Shacey 4

4 · EXACT SCIENCES CORP · Filed Mar 23, 2026

AI-generated summary of this filing

Updated Mar 23, 2026

Exact Sciences (EXAS) Director Shacey Petrovic Sells 28,899 Shares

What Happened

Shacey Petrovic, a director of Exact Sciences Corporation (EXAS), had a total of 28,899 shares disposed on March 23, 2026 via dispositions to the issuer in connection with the company’s merger with Abbott. The merger converted each share of EXAS common stock into $105.00 in cash, so the converted shares correspond to approximately $3,034,395 in aggregate consideration.
These were not open-market sales but conversions of outstanding shares (including vested/restricted shares) into cash under the Merger Agreement.

Key Details

Transaction date: March 23, 2026 (Effective Time of the merger).
Shares disposed: 16,406 + 5,398 + 7,095 = 28,899 shares.
Per-share consideration: $105.00; aggregate ≈ $3,034,395.
Disposition type: "D" — disposition to the issuer pursuant to the Merger Agreement (not an open-market sale).
Footnotes: Under the Merger Agreement (dated Nov 19, 2025), each outstanding share (with certain exceptions) was converted into $105 cash (F1). Shares subject to vesting/repurchase restrictions were deemed fully vested, cancelled, and converted into cash less any applicable tax withholding (F2).
Shares owned after the transaction: the Form 4 reports these dispositions as conversion into cash; the filing does not list remaining EXAS common shares post-merger for these lots.
Filing timeliness: Reported on March 23, 2026 (same date as the Effective Time), indicating a timely post-merger filing.

Context

These transactions reflect merger consideration paid by Abbott upon its acquisition of Exact Sciences, not discretionary insider selling. Conversions of restricted/vested shares into cash upon a takeover are routine and are driven by transaction terms rather than an insider trading decision.
Retail investors should view this as a corporate liquidity event (cash-out) rather than a signal of insider sentiment about the company's future stock performance.

Form 4Exit

Period: 2026-03-23

Director

Transactions

Disposition to Issuer
Common Stock
[F1]
2026-03-23−16,406→ 5,398 total
Disposition to Issuer
Common Stock
[F2]
2026-03-23−5,398→ 0 total
Disposition to Issuer
Common Stock
[F1]
2026-03-23−7,095→ 0 total(indirect: By Trust)

Footnotes (2)

[F1]On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration").
[F2]At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.

Signature

/s/ Shacey Petrovic by Mark Busch, attorney-in- fact|2026-03-23

1 file